Nemolizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Nemolizumab: From Atopic Dermatitis / Prurigo Nodularis Pruritus to Diabetic Cataract
One-Sentence Summary
Nemolizumab is an anti-IL-31 receptor A monoclonal antibody, used for itch associated with atopic dermatitis and prurigo nodularis. The TxGNN model predicts it may be effective for diabetic cataract, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data. Per pharmacology data, approved elsewhere for pruritus in atopic dermatitis (Japan) and prurigo nodularis (FDA) |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.55% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Nemolizumab blocks the interleukin-31 receptor alpha subunit (IL31RA), which dampens IL-31 signalling that drives itch and skin inflammation. Detailed mechanism of action data is not available in the data compiled for this report. The mechanism above comes from the drug's target pharmacology.
A plausible link between this mechanism and diabetic cataract has not been identified. Cataract formation in diabetes is mainly metabolic: high glucose, sorbitol accumulation through the polyol pathway, oxidative stress and protein aggregation in the lens. IL-31 signalling is not an established part of this process.
The high score (0.986) is most likely a graph-based signal. Several cataract subtypes (immature, mature, tetanic, craniostenosis-associated, type 2 diabetes-associated, nuclear senile, cortical and senile) received nearly identical scores of about 98.4% to 98.5%. This suggests one shared network signal rather than independent evidence. The most biologically conceivable prediction on the list is diabetic retinopathy (score 98.24%), where inflammation plays a role. Even there, IL-31/IL-31RA has no established role in the retina, and the link is speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17206P | NEMLUVIO powder and solvent for solution for injection in pre-filled pen 30 mg | Lyophilised powder for injection | Not available in licence data |
| SIN17207P | NEMLUVIO powder and solvent for solution for injection in pre-filled syringe 30 mg | Lyophilised powder for injection | Not available in licence data |
Safety Considerations
- Drug Interactions: The only interaction record is a pharmacological target entry (IL-31 receptor alpha subunit), which is the drug's intended target. It is not a drug–drug interaction. Nemolizumab is an antibody. A Phase 1 study of it reported no serious adverse events.
Please refer to the package insert for warnings and contraindications, which were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical, preclinical or mechanistic support. The score appears to come from graph similarity across the cataract disease cluster. Nothing biologically links IL-31 receptor blockade to lens opacification. Warnings and contraindications from the package insert are also missing, so safety screening cannot proceed.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, to allow safety screening
- Detailed mechanism of action data
- Preclinical evidence that IL-31 signalling contributes to lens opacification, or to diabetic eye disease
- A safety rationale for systemic biologic exposure in an ocular indication
- Consider re-examining diabetic retinopathy as a more biologically plausible candidate, though it is still prediction-only
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.